Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability
Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One h...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2011-02, Vol.125 (3), p.741-749 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 749 |
|---|---|
| container_issue | 3 |
| container_start_page | 741 |
| container_title | Breast cancer research and treatment |
| container_volume | 125 |
| creator | Dixon, J. Michael Renshaw, Lorna Langridge, Carolyn Young, Oliver E McHugh, Mary Williams, Linda Murray, Juliette Macaskill, E. Jane McCaig, Fiona Dixon, Oliver M Fallowfield, Lesley J |
| description | Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence. One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy. The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug. Additional side-effect profiles were collected. Each patient completed a patient preference form. Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P = 0.12). Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001). There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs. Nearly 80% of patients reported one or more side effects with either agent. No differences in frequency, grade, or range of side effects were seen between drugs. Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P = 0.26, Pearson's Chi-squared test). In conclusion, both AIs are equally well tolerated. There were no significant differences in QOL scores between the two drugs. |
| doi_str_mv | 10.1007/s10549-010-1091-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_00574006v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A356142669</galeid><sourcerecordid>A356142669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c599t-e8261dabea5546d37032b6d5c194d60b7a2a0ce0cc34cb781862c98ff8f3ad83</originalsourceid><addsrcrecordid>eNp9kk9v1DAQxSMEoqXwAbjAqggQh5SxE__jtqqAIq3EgXLFmjjOritvvLWTSuXT4zRLSxFCPsQz83svmuQVxXMCJwRAvE8EWK1KIFASUKRUD4pDwkRVCkrEw-IQCBcll8APiicpXQCAEqAeFwcUJCVQi8Pix7LHNMTwM3i7wL5deLuvPuRy4formwa3xsGF_mZuwnaH0aVchm5xOaJ3w_V09a6bHYYsjti4afC0eNShT_bZ_nlUnH_6eH56Vq6-fv5yulyVhik1lFZSTlpsLDJW87YSUNGGt8wQVbccGoEUwVgwpqpNIySRnBolu052FbayOirezbYb9HoX3RbjtQ7o9NlypaceABM1AL8imX07s7sYLse8nd66ZKz32NswJi1rroBINrke_0VehDH2eY8MsWwnJcvQqxlao7fa9V0YIprJUi8rxklNOVeZOvkHlU9rt86E3nYu9-8J3vwh2Fj0wyYFP07_Id0HyQyaGFKKtrvdn4CeUqLnlGi4qRXRk-bFfrGx2dr2VvE7Fhl4vQcwGfRdxN64dMdVQomcq8zRmUt51K9tvPtC_3v7y1nUYdC4zlnS379RIBUQRaUgUP0Ch6vajQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>845400885</pqid></control><display><type>article</type><title>Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Dixon, J. Michael ; Renshaw, Lorna ; Langridge, Carolyn ; Young, Oliver E ; McHugh, Mary ; Williams, Linda ; Murray, Juliette ; Macaskill, E. Jane ; McCaig, Fiona ; Dixon, Oliver M ; Fallowfield, Lesley J</creator><creatorcontrib>Dixon, J. Michael ; Renshaw, Lorna ; Langridge, Carolyn ; Young, Oliver E ; McHugh, Mary ; Williams, Linda ; Murray, Juliette ; Macaskill, E. Jane ; McCaig, Fiona ; Dixon, Oliver M ; Fallowfield, Lesley J</creatorcontrib><description>Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence. One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy. The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug. Additional side-effect profiles were collected. Each patient completed a patient preference form. Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P = 0.12). Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001). There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs. Nearly 80% of patients reported one or more side effects with either agent. No differences in frequency, grade, or range of side effects were seen between drugs. Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P = 0.26, Pearson's Chi-squared test). In conclusion, both AIs are equally well tolerated. There were no significant differences in QOL scores between the two drugs.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-010-1091-9</identifier><identifier>PMID: 20821047</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Boston : Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Anastrozole ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Breast cancer ; breast neoplasms ; Breast Neoplasms - drug therapy ; Cancer research ; Cancer therapies ; Clinical Trial ; Clinical trials ; Comparative studies ; Cross-Over Studies ; Drug therapy ; Endocrine System ; Estrogen ; Gynecology. Andrology. Obstetrics ; Health aspects ; Humans ; Investigations ; Letrozole ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Nitriles - therapeutic use ; Oncology ; Postmenopausal women ; Quality of Life ; Side effects ; tamoxifen ; Tamoxifen - therapeutic use ; Treatment Outcome ; Triazoles - therapeutic use ; Tumors</subject><ispartof>Breast cancer research and treatment, 2011-02, Vol.125 (3), p.741-749</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer Science+Business Media, LLC. 2011</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c599t-e8261dabea5546d37032b6d5c194d60b7a2a0ce0cc34cb781862c98ff8f3ad83</citedby><cites>FETCH-LOGICAL-c599t-e8261dabea5546d37032b6d5c194d60b7a2a0ce0cc34cb781862c98ff8f3ad83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-010-1091-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-010-1091-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23797680$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20821047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-00574006$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Dixon, J. Michael</creatorcontrib><creatorcontrib>Renshaw, Lorna</creatorcontrib><creatorcontrib>Langridge, Carolyn</creatorcontrib><creatorcontrib>Young, Oliver E</creatorcontrib><creatorcontrib>McHugh, Mary</creatorcontrib><creatorcontrib>Williams, Linda</creatorcontrib><creatorcontrib>Murray, Juliette</creatorcontrib><creatorcontrib>Macaskill, E. Jane</creatorcontrib><creatorcontrib>McCaig, Fiona</creatorcontrib><creatorcontrib>Dixon, Oliver M</creatorcontrib><creatorcontrib>Fallowfield, Lesley J</creatorcontrib><title>Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence. One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy. The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug. Additional side-effect profiles were collected. Each patient completed a patient preference form. Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P = 0.12). Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001). There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs. Nearly 80% of patients reported one or more side effects with either agent. No differences in frequency, grade, or range of side effects were seen between drugs. Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P = 0.26, Pearson's Chi-squared test). In conclusion, both AIs are equally well tolerated. There were no significant differences in QOL scores between the two drugs.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Anastrozole</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>breast neoplasms</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Clinical Trial</subject><subject>Clinical trials</subject><subject>Comparative studies</subject><subject>Cross-Over Studies</subject><subject>Drug therapy</subject><subject>Endocrine System</subject><subject>Estrogen</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Investigations</subject><subject>Letrozole</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nitriles - therapeutic use</subject><subject>Oncology</subject><subject>Postmenopausal women</subject><subject>Quality of Life</subject><subject>Side effects</subject><subject>tamoxifen</subject><subject>Tamoxifen - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kk9v1DAQxSMEoqXwAbjAqggQh5SxE__jtqqAIq3EgXLFmjjOritvvLWTSuXT4zRLSxFCPsQz83svmuQVxXMCJwRAvE8EWK1KIFASUKRUD4pDwkRVCkrEw-IQCBcll8APiicpXQCAEqAeFwcUJCVQi8Pix7LHNMTwM3i7wL5deLuvPuRy4formwa3xsGF_mZuwnaH0aVchm5xOaJ3w_V09a6bHYYsjti4afC0eNShT_bZ_nlUnH_6eH56Vq6-fv5yulyVhik1lFZSTlpsLDJW87YSUNGGt8wQVbccGoEUwVgwpqpNIySRnBolu052FbayOirezbYb9HoX3RbjtQ7o9NlypaceABM1AL8imX07s7sYLse8nd66ZKz32NswJi1rroBINrke_0VehDH2eY8MsWwnJcvQqxlao7fa9V0YIprJUi8rxklNOVeZOvkHlU9rt86E3nYu9-8J3vwh2Fj0wyYFP07_Id0HyQyaGFKKtrvdn4CeUqLnlGi4qRXRk-bFfrGx2dr2VvE7Fhl4vQcwGfRdxN64dMdVQomcq8zRmUt51K9tvPtC_3v7y1nUYdC4zlnS379RIBUQRaUgUP0Ch6vajQ</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Dixon, J. Michael</creator><creator>Renshaw, Lorna</creator><creator>Langridge, Carolyn</creator><creator>Young, Oliver E</creator><creator>McHugh, Mary</creator><creator>Williams, Linda</creator><creator>Murray, Juliette</creator><creator>Macaskill, E. Jane</creator><creator>McCaig, Fiona</creator><creator>Dixon, Oliver M</creator><creator>Fallowfield, Lesley J</creator><general>Boston : Springer US</general><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope></search><sort><creationdate>20110201</creationdate><title>Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability</title><author>Dixon, J. Michael ; Renshaw, Lorna ; Langridge, Carolyn ; Young, Oliver E ; McHugh, Mary ; Williams, Linda ; Murray, Juliette ; Macaskill, E. Jane ; McCaig, Fiona ; Dixon, Oliver M ; Fallowfield, Lesley J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c599t-e8261dabea5546d37032b6d5c194d60b7a2a0ce0cc34cb781862c98ff8f3ad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Anastrozole</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>breast neoplasms</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Clinical Trial</topic><topic>Clinical trials</topic><topic>Comparative studies</topic><topic>Cross-Over Studies</topic><topic>Drug therapy</topic><topic>Endocrine System</topic><topic>Estrogen</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Investigations</topic><topic>Letrozole</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nitriles - therapeutic use</topic><topic>Oncology</topic><topic>Postmenopausal women</topic><topic>Quality of Life</topic><topic>Side effects</topic><topic>tamoxifen</topic><topic>Tamoxifen - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dixon, J. Michael</creatorcontrib><creatorcontrib>Renshaw, Lorna</creatorcontrib><creatorcontrib>Langridge, Carolyn</creatorcontrib><creatorcontrib>Young, Oliver E</creatorcontrib><creatorcontrib>McHugh, Mary</creatorcontrib><creatorcontrib>Williams, Linda</creatorcontrib><creatorcontrib>Murray, Juliette</creatorcontrib><creatorcontrib>Macaskill, E. Jane</creatorcontrib><creatorcontrib>McCaig, Fiona</creatorcontrib><creatorcontrib>Dixon, Oliver M</creatorcontrib><creatorcontrib>Fallowfield, Lesley J</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dixon, J. Michael</au><au>Renshaw, Lorna</au><au>Langridge, Carolyn</au><au>Young, Oliver E</au><au>McHugh, Mary</au><au>Williams, Linda</au><au>Murray, Juliette</au><au>Macaskill, E. Jane</au><au>McCaig, Fiona</au><au>Dixon, Oliver M</au><au>Fallowfield, Lesley J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>125</volume><issue>3</issue><spage>741</spage><epage>749</epage><pages>741-749</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Previous studies have demonstrated that both anastrozole and letrozole are well tolerated. Letrozole suppresses estrogen to a greater degree than anastrozole in the serum and breast tumor. Concerns have been raised that greater potency may adversely affect patients' quality of life (QOL). One hundred eighty-one postmenopausal women with invasive estrogen receptor-positive breast cancers were randomized to receive either 12 weeks of letrozole followed by 12 weeks of anastrozole or the reverse sequence. One hundred and six received immediate adjuvant aromatase inhibitors (AIs) following surgery, and 75 received extended adjuvant therapy. The Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-B-ES) QOL questionnaires were completed to assess QOL on each drug. Additional side-effect profiles were collected. Each patient completed a patient preference form. Twenty-one patients withdrew before study end, 10/179 (5.6%) while taking letrozole and 4/173 (2.3%) while taking anastrozole (P = 0.12). Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001). There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs. Nearly 80% of patients reported one or more side effects with either agent. No differences in frequency, grade, or range of side effects were seen between drugs. Of 160 patients, 49 (30.6%) preferred letrozole, 57 (35.6%) preferred anastrozole, and 54 (33.8%) had no preference (P = 0.26, Pearson's Chi-squared test). In conclusion, both AIs are equally well tolerated. There were no significant differences in QOL scores between the two drugs.</abstract><cop>Boston</cop><pub>Boston : Springer US</pub><pmid>20821047</pmid><doi>10.1007/s10549-010-1091-9</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2011-02, Vol.125 (3), p.741-749 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_00574006v1 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Analysis Anastrozole Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Breast cancer breast neoplasms Breast Neoplasms - drug therapy Cancer research Cancer therapies Clinical Trial Clinical trials Comparative studies Cross-Over Studies Drug therapy Endocrine System Estrogen Gynecology. Andrology. Obstetrics Health aspects Humans Investigations Letrozole Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Nitriles - therapeutic use Oncology Postmenopausal women Quality of Life Side effects tamoxifen Tamoxifen - therapeutic use Treatment Outcome Triazoles - therapeutic use Tumors |
| title | Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A56%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anastrozole%20and%20letrozole:%20an%20investigation%20and%20comparison%20of%20quality%20of%20life%20and%20tolerability&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Dixon,%20J.%20Michael&rft.date=2011-02-01&rft.volume=125&rft.issue=3&rft.spage=741&rft.epage=749&rft.pages=741-749&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-010-1091-9&rft_dat=%3Cgale_hal_p%3EA356142669%3C/gale_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=845400885&rft_id=info:pmid/20821047&rft_galeid=A356142669&rfr_iscdi=true |